At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 737 enrolled
Drug / intervention
Peginterferon alfa-2a +1 moredrug
Likely dose
Peginterferon alfa-2a 180 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Multicenter Study to Find Optimal Treatment Duration in Patients With Chronic Hepatitis C and Subtype 1 or 4 Depending on HCV RNA Level at Week 8 and Week 12
In Brief
A Phase 4 clinical trial evaluating Peginterferon alfa-2a and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 737 participants across 21 sites.
Detailed Summary
This study will compare the efficacy and safety of 2 different treatment durations of peginterferon alfa-2a (Pegasys) plus ribavirin in patients with CHC. The anticipated time on study treatment is 1-2 years, and the target sample size is greater than (\>) 500 individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesAustria
Collaborators--
Timeline
Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2003
Primary CompletionNov 2013
First PostedDec 2015
TodayJul 2026
First PostedDec 29, 2015
Enrollment StartMay 1, 2003
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10.5 yearsPosted 10.5 years ago
Interventions
Peginterferon alfa-2adrug
PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n
Ribavirindrug
Ribavirin is available as 200 mg tablets